{
    "clinical_study": {
        "@rank": "11754", 
        "acronym": "AG-348 SAD", 
        "arm_group": [
            {
                "arm_group_label": "AG-348", 
                "arm_group_type": "Experimental", 
                "description": "Single oral dose of AG-348"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Single oral dose of placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a dose escalation study that will be conducted in healthy volunteers.  Multiple\n      cohorts of volunteers will receive ascending oral doses of AG-348 to evaluate the safety and\n      tolerability of a single oral dose of AG-348, the pharmacokinetics (PK) of a single dose of\n      AG-348, and the pharmacodynamic profile of AG-348 with specific biomarkers assessed in the\n      blood."
        }, 
        "brief_title": "A Phase I Study of AG-348 in Healthy Volunteers", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adult male or female subjects 18 - 60 years, in good general health who are\n             able to understand consent and complete all study procedures.\n\n          -  Female subjects of non-child bearing potential (surgically sterile or post-menopausal\n             as confirmed by age [over 50 years], amenorrhea for 12 consecutive months and FSH).\n\n          -  Male subjects who are not vasectomized must agree to use contraception up to 30 days\n             after dosing.\n\n          -  Subjects with body weight \u226550 kg; BMI \u226518.5 and \u226432 kg/m2.\n\n          -  Subjects who are non-smokers and have not used nicotine containing products for at\n             least 3 months prior to screening.\n\n          -  Subjects must be willing to refrain from caffeine- or xanthene containing products\n             (chocolate) prior to dosing through 72 hours after dosing.\n\n          -  Subjects must agree to refrain from strenuous exercise prior to admission through\n             final visit.\n\n          -  Subjects must refrain from use of alcohol starting 7 days prior to admission through\n             final visit.\n\n          -  Subjects must agree not to donate blood products for duration of study participation.\n\n        Exclusion Criteria:\n\n          -  Subjects who have previously received AG-348.\n\n          -  Subjects with clinically relevant screening laboratory tests.\n\n          -  Female subjects of childbearing potential.\n\n          -  Male subjects with QTcF interval ECG > 450 msec,or female subjects with QTcF interval\n             ECG > 470 msec.\n\n          -  Subjects with a history of a serious mental illness.\n\n          -  Subjects with a clinically relevant medical history or pre-existing medical condition\n             that would interfere with the absorption, metabolism or excretion of the study drug.\n\n          -  Subjects with a history of any primary malignancy (cancer).  Exceptions are certain\n             skin cancers, cervical cancer in situ or other cancers that have been curatively\n             treated without evidence of disease for a minimum of 1 year.\n\n          -  Subjects with glucose-6-phosphate-dehydrogenase (G6PD) deficiency.\n\n          -  Subjects who are positive for hepatitis B, hepatitis C or HIV.\n\n          -  Subjects who have undergone surgery 6 months prior to screening.\n\n          -  Subjects who have a history of illicit drug use or alcoholism within the last year.\n\n          -  Subjects who are participating in other concurrent clinical trial of an\n             investigational drug, or have received another investigational agent within the last\n             2 months.\n\n          -  Subjects with any conditions which would make the subject unsuitable for enrollment,\n             or could interfere with the subject's participation in or completion of the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02108106", 
            "org_study_id": "AG348-C-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "AG-348", 
                "description": "A range of doses of AG-348 will be tested based on assessment of safety and tolerability.", 
                "intervention_name": "AG-348", 
                "intervention_type": "Drug", 
                "other_name": "AG-348 will be administered as a single oral dose on Day 1."
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo will be administered as a single oral dose on Day 1."
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "safety and tolerability", 
            "pharmacokinetic study"
        ], 
        "lastchanged_date": "April 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21225"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Safety, Pharmacokinetic and Pharmacodynamic Study of Orally Administered AG-348 in Healthy Volunteers", 
        "overall_contact": {
            "email": "elizabeth.merica@agis.com", 
            "last_name": "Elizabeth Merica", 
            "phone": "617-649-2034"
        }, 
        "overall_contact_backup": {
            "email": "caroline.almon@agios.com", 
            "last_name": "Caroline Almon, M.S.", 
            "phone": "617-649-8500"
        }, 
        "overall_official": {
            "affiliation": "Agios Pharmaceuticals, Inc.", 
            "last_name": "Samuel Agresta, MD, MPH & TM", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence of adverse events and descriptive statistics for safety laboratory parameters, physical exam findings, vital signs and ECGs.", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "11 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02108106"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Descriptive statistics will be used to summarize PK parameters of AG-348 for each dose group and, where appropriate, for the entire population. Standard non-compartmental PK parameters will be calculated from individual plasma concentration data.", 
                "measure": "Pharmacokinetics of AG-348", 
                "safety_issue": "Yes", 
                "time_frame": "4 days"
            }, 
            {
                "description": "The potential relationship between AG-348 and metabolic biomarkers will be explored with descriptive and graphical methods. Details on the evaluation of exploratory analyses of pyruvate kinase (PKR) activity and other potential PD biomarkers will be described.", 
                "measure": "Pharmacodynamic (PD) relationship of AG-348 and metabolic biomarkers", 
                "safety_issue": "No", 
                "time_frame": "4 days"
            }
        ], 
        "source": "Agios Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Agios Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}